Niagen Bioscience Reports Strong Q1 2026 Earnings with Growth Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NAGE?
Source: seekingalpha
- Revenue Growth: Niagen Bioscience reported $31.5 million in revenue for Q1 2026, exceeding analyst expectations of $31.0256 million, with a net income of $6.3 million, reflecting a 14% year-over-year growth in its e-commerce segment, although reduced orders from some customers impacted overall growth.
- New Product Launches: The company introduced the Niagen+ at-home injection kit and the Niagen Nanocloud skincare product, with the former receiving strong market response and the latter nearly sold out during its pilot phase, set for a wide launch in October, which will enhance the product portfolio and drive future sales.
- Expense Adjustments: Management anticipates an increase in selling and marketing expenses in absolute dollars and as a percentage of net sales, reflecting the company's focus on marketing to address competitive pressures and enhance brand visibility.
- Cash Flow Dynamics: Despite a net cash usage of $1.2 million in operations during Q1, primarily due to inventory investments and the impact of Amazon's sales policy, management remains optimistic about achieving a 10%-15% revenue growth outlook for the year, demonstrating resilience in the face of challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.190
Low
12.00
Averages
16.33
High
23.00
Current: 4.190
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen Bioscience Announces Upcoming Conference Participation
- Conference Schedule: Niagen Bioscience will participate in the 31st Annual Sohn Investment Conference on May 12, 2026, where CFO Ozan Pamir will showcase the company's focus on the science of healthy aging in the Emerging Company Pavilion.
- One-on-One Meetings: At the 4th Annual Benchmark Consumer One-On-One Conference on May 19, 2026, CEO Rob Fried and CFO Ozan Pamir will engage in one-on-one discussions with investors, enhancing connections with potential stakeholders.
- NAD+ Scientific Leadership: As a global authority on NAD+ science, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, highlighting its leadership in aging research.
- Product Advantages: Niagen® is the most effective NAD+ booster on the market, supporting Tru Niagen® as the number one NAD+ boosting oral supplement in the U.S., further solidifying the company's competitive edge in the health supplement market.
See More
Niagen Bioscience Reports Strong Q1 2026 Earnings with Growth Challenges
- Revenue Growth: Niagen Bioscience reported $31.5 million in revenue for Q1 2026, exceeding analyst expectations of $31.0256 million, with a net income of $6.3 million, reflecting a 14% year-over-year growth in its e-commerce segment, although reduced orders from some customers impacted overall growth.
- New Product Launches: The company introduced the Niagen+ at-home injection kit and the Niagen Nanocloud skincare product, with the former receiving strong market response and the latter nearly sold out during its pilot phase, set for a wide launch in October, which will enhance the product portfolio and drive future sales.
- Expense Adjustments: Management anticipates an increase in selling and marketing expenses in absolute dollars and as a percentage of net sales, reflecting the company's focus on marketing to address competitive pressures and enhance brand visibility.
- Cash Flow Dynamics: Despite a net cash usage of $1.2 million in operations during Q1, primarily due to inventory investments and the impact of Amazon's sales policy, management remains optimistic about achieving a 10%-15% revenue growth outlook for the year, demonstrating resilience in the face of challenges.
See More
Niagen (NAGE) Q1 2026 Earnings Call Transcript
See More
Niagen Launches Telehealth Platform with At-Home Injection Kit
- Telehealth Innovation: Niagen Bioscience's launch of the Niagen™Plus platform allows U.S. patients to access prescription-only pharmaceutical-grade Niagen At-Home Injection Kit from home, marking the company's first direct-to-client model that enhances patient convenience and accessibility.
- Significant Market Potential: According to Future Market Insights, the U.S. injectable industry was valued at $223.6 billion in 2025, with a projected CAGR of 6.8% through 2035, indicating strong demand and growth potential in this sector.
- Safety Validation: In clinical safety trials, the Niagen injection kit was generally considered safe and well-tolerated at dosages of 50 mg/mL and 100 mg/mL, demonstrating its effectiveness and reliability in providing cellular health support.
- Scientific Rigor: The platform emphasizes clinical oversight and quality standards, ensuring that patients can receive pharmaceutical-grade Niagen at home while still benefiting from professional medical guidance, thereby enhancing consumer trust in the brand.
See More
Niagen Partners with Olympia to Expand Pharmaceutical Supply Chain
- Network Expansion: Niagen Bioscience's new partnership with Olympia Pharmaceuticals leverages Olympia's FDA-registered 503B outsourcing facility to enhance the distribution capabilities of Niagen Plus products, which is expected to significantly increase the company's market share in the healthy aging sector to meet rising demand.
- Product Innovation: The introduction of Niagen Bioscience's next-generation pharmaceutical-grade Niagen IV formulation supports faster infusion rates and elevates NAD+ levels while minimizing side effects associated with traditional NAD+ IV, likely attracting more customers seeking solutions for healthy aging and driving sales growth.
- Intellectual Property Expansion: The company recently secured a new patent covering the use of Niagen and its derivatives in IV and injectable formulations, which not only protects its market position but also provides legal assurance for future product development, enhancing the company's competitive edge.
- Quality Assurance Commitment: Olympia Pharmaceuticals is renowned for its high-quality compounded medications and stringent compliance standards, adhering to cGMP guidelines to ensure a stable supply of high-quality pharmaceuticals, which will strongly support the market promotion of Niagen Plus and enhance customer trust.
See More
Niagen Bioscience to Host Q1 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on May 6, 2026, at 4:30 p.m. ET to discuss its Q1 financial results, reflecting the company's commitment to transparency and investor communication.
- Webcast Details: The call will be available via live webcast, accessible through the company's website, showcasing its modernization efforts in digital communication and enhancing investor engagement.
- Dial-in Information: Investors can join the call by dialing 1 (833) 461-5787 with Conference ID: 828848803, ensuring easy access to financial information and improving information retrieval convenience.
- Replay Availability: The recorded webcast will be available for replay from 7:30 p.m. ET on May 6, 2026, to 11:59 p.m. ET on May 6, 2027, further enhancing information accessibility and allowing investors to revisit key content at their convenience.
See More
Niagen Bioscience Announces Upcoming Conference Participation
- Conference Schedule: Niagen Bioscience will participate in the 31st Annual Sohn Investment Conference on May 12, 2026, where CFO Ozan Pamir will showcase the company's focus on the science of healthy aging in the Emerging Company Pavilion.
- One-on-One Meetings: At the 4th Annual Benchmark Consumer One-On-One Conference on May 19, 2026, CEO Rob Fried and CFO Ozan Pamir will engage in one-on-one discussions with investors, enhancing connections with potential stakeholders.
- NAD+ Scientific Leadership: As a global authority on NAD+ science, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, highlighting its leadership in aging research.
- Product Advantages: Niagen® is the most effective NAD+ booster on the market, supporting Tru Niagen® as the number one NAD+ boosting oral supplement in the U.S., further solidifying the company's competitive edge in the health supplement market.
See More
Niagen Bioscience Reports Strong Q1 2026 Earnings with Growth Challenges
- Revenue Growth: Niagen Bioscience reported $31.5 million in revenue for Q1 2026, exceeding analyst expectations of $31.0256 million, with a net income of $6.3 million, reflecting a 14% year-over-year growth in its e-commerce segment, although reduced orders from some customers impacted overall growth.
- New Product Launches: The company introduced the Niagen+ at-home injection kit and the Niagen Nanocloud skincare product, with the former receiving strong market response and the latter nearly sold out during its pilot phase, set for a wide launch in October, which will enhance the product portfolio and drive future sales.
- Expense Adjustments: Management anticipates an increase in selling and marketing expenses in absolute dollars and as a percentage of net sales, reflecting the company's focus on marketing to address competitive pressures and enhance brand visibility.
- Cash Flow Dynamics: Despite a net cash usage of $1.2 million in operations during Q1, primarily due to inventory investments and the impact of Amazon's sales policy, management remains optimistic about achieving a 10%-15% revenue growth outlook for the year, demonstrating resilience in the face of challenges.
See More
Niagen (NAGE) Q1 2026 Earnings Call Transcript
See More
Niagen Launches Telehealth Platform with At-Home Injection Kit
- Telehealth Innovation: Niagen Bioscience's launch of the Niagen™Plus platform allows U.S. patients to access prescription-only pharmaceutical-grade Niagen At-Home Injection Kit from home, marking the company's first direct-to-client model that enhances patient convenience and accessibility.
- Significant Market Potential: According to Future Market Insights, the U.S. injectable industry was valued at $223.6 billion in 2025, with a projected CAGR of 6.8% through 2035, indicating strong demand and growth potential in this sector.
- Safety Validation: In clinical safety trials, the Niagen injection kit was generally considered safe and well-tolerated at dosages of 50 mg/mL and 100 mg/mL, demonstrating its effectiveness and reliability in providing cellular health support.
- Scientific Rigor: The platform emphasizes clinical oversight and quality standards, ensuring that patients can receive pharmaceutical-grade Niagen at home while still benefiting from professional medical guidance, thereby enhancing consumer trust in the brand.
See More
Niagen Partners with Olympia to Expand Pharmaceutical Supply Chain
- Network Expansion: Niagen Bioscience's new partnership with Olympia Pharmaceuticals leverages Olympia's FDA-registered 503B outsourcing facility to enhance the distribution capabilities of Niagen Plus products, which is expected to significantly increase the company's market share in the healthy aging sector to meet rising demand.
- Product Innovation: The introduction of Niagen Bioscience's next-generation pharmaceutical-grade Niagen IV formulation supports faster infusion rates and elevates NAD+ levels while minimizing side effects associated with traditional NAD+ IV, likely attracting more customers seeking solutions for healthy aging and driving sales growth.
- Intellectual Property Expansion: The company recently secured a new patent covering the use of Niagen and its derivatives in IV and injectable formulations, which not only protects its market position but also provides legal assurance for future product development, enhancing the company's competitive edge.
- Quality Assurance Commitment: Olympia Pharmaceuticals is renowned for its high-quality compounded medications and stringent compliance standards, adhering to cGMP guidelines to ensure a stable supply of high-quality pharmaceuticals, which will strongly support the market promotion of Niagen Plus and enhance customer trust.
See More
Niagen Bioscience to Host Q1 Earnings Call
- Earnings Call Announcement: Niagen Bioscience will hold a conference call on May 6, 2026, at 4:30 p.m. ET to discuss its Q1 financial results, reflecting the company's commitment to transparency and investor communication.
- Webcast Details: The call will be available via live webcast, accessible through the company's website, showcasing its modernization efforts in digital communication and enhancing investor engagement.
- Dial-in Information: Investors can join the call by dialing 1 (833) 461-5787 with Conference ID: 828848803, ensuring easy access to financial information and improving information retrieval convenience.
- Replay Availability: The recorded webcast will be available for replay from 7:30 p.m. ET on May 6, 2026, to 11:59 p.m. ET on May 6, 2027, further enhancing information accessibility and allowing investors to revisit key content at their convenience.
See More
